We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoassay Determines Thiopurine Methlytransferase Activity in Erythrocytes

By LabMedica International staff writers
Posted on 08 Sep 2008
A new TPMT activity assay is a competitive microwell immunoassay for the semi-quantitative determination of thiopurine methlytransferase (TPMT) activity in erythrocytes. More...


The level of patient TPMT activity is the best indicator for an individual patient's ability to metabolize specific medicines, avoid toxicities, and their individual therapeutic efficacy. These drugs are typically used for the treatment of inflammatory bowel diseases (IBDs), leukemia, and many other medical disorders.

TPMT catalyzes the S-methylation of 6-mercaptopurine (6-MP) with the presence of S-adenosylmethionine (SAM), the methyl donor, yielding 6-methylmercaptopurine (6-MMP). 6-MMP, a small molecule, is then measured with a microwell enzyme immunoassay (EIA).

The successful development of specific antibodies against 6-MMP and the introduction of the harsh methylation reaction product mix into the delicate immunoassay environment mark a technologic breakthrough. This new assay system brings clinicians and patients tremendous benefits in the area of clinical pharmacogenomics.

Biologix Diagnostics, LLC (Lenexa, KS, USA) announced that its new technology is now available for sale worldwide.

Related Links:
Biologix Diagnostics


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.